Responses
Regular and young investigator award abstracts
Clinical trials in progress
347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
